| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Li-Hua Lo, Jentaie Shiea, Tiao-Lai Huan. Rapid detection of alteration of serum IgG in patients with schizophrenia after risperidone treatment by matrix-assisted laser desorption ionization/time-of-flight mass spectrometry. Rapid communications in mass spectrometry : RCM. vol 30. issue 24. 2018-02-02. PMID:27699909. |
the aim of the study was to use a technique that combines acid hydrolysis and matrix-assisted laser desorption ionization/time-of-flight mass spectrometry (maldi-tof ms) in order to detect the serum biomarkers of patients diagnosed with schizophrenia both before and after four-week antipsychotic treatment with risperidone. |
2018-02-02 |
2023-08-13 |
Not clear |
| Bart Remmerie, Marc De Meulder, Jay Ariyawansa, Adam Savit. Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole. Clinical pharmacology in drug development. vol 5. issue 6. 2018-01-29. PMID:27363344. |
this open-label, parallel-group study was performed to compare finger-stick-based capillary with corresponding venous plasma concentrations for risperidone, paliperidone, quetiapine, olanzapine, and aripiprazole and their major metabolites after repeated dosing in patients with schizophrenia or related illnesses. |
2018-01-29 |
2023-08-13 |
Not clear |
| Bart Remmerie, Marc De Meulder, Sveta Weiner, Adam Savit. Comparison of Capillary and Venous Drug Concentrations After Administration of a Single Dose of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole. Clinical pharmacology in drug development. vol 5. issue 6. 2018-01-29. PMID:27365164. |
risperidone, paliperidone, quetiapine, olanzapine, and aripiprazole are antipsychotic drugs approved for treating various psychiatric disorders, including schizophrenia. |
2018-01-29 |
2023-08-13 |
human |
| Monica M Marcus, Carl Björkholm, Anna Malmerfelt, Annie Möller, Ninni Påhlsson, Åsa Konradsson-Geuken, Kristin Feltmann, Kent Jardemark, Björn Schilström, Torgny H Svensso. Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 26. issue 9. 2018-01-18. PMID:27474687. |
in the present study we investigated, in rats, the effects of a selective α7 agonist (pnu282987) and a α7 positive allosteric modulator (pam; ns1738) alone and in combination with the atypical antipsychotic drug risperidone for their utility as adjunct treatment in schizophrenia. |
2018-01-18 |
2023-08-13 |
rat |
| Marise Wj Machielsen, Dick J Veltman, Wim van den Brink, Lieuwe de Haa. The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study. Journal of psychopharmacology (Oxford, England). vol 28. issue 7. 2018-01-16. PMID:24646809. |
the effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: an fmri study. |
2018-01-16 |
2023-08-12 |
Not clear |
| Marise Wj Machielsen, Dick J Veltman, Wim van den Brink, Lieuwe de Haa. The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study. Journal of psychopharmacology (Oxford, England). vol 28. issue 7. 2018-01-16. PMID:24646809. |
we compared the effects of clozapine and risperidone on attentional bias, subjective craving and associated regional brain activity in patients with schizophrenia and cud. |
2018-01-16 |
2023-08-12 |
Not clear |
| Marise Wj Machielsen, Dick J Veltman, Wim van den Brink, Lieuwe de Haa. The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study. Journal of psychopharmacology (Oxford, England). vol 28. issue 7. 2018-01-16. PMID:24646809. |
these findings strongly suggest that clozapine may be a better treatment choice in patients with schizophrenia and cud than risperidone. |
2018-01-16 |
2023-08-12 |
Not clear |
| John J Isitt, Vijay R Nadipelli, Alex Kouassi, Maurizio Fava, Christian Heidbrede. Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. Schizophrenia research. vol 174. issue 1-3. 2018-01-05. PMID:27066860. |
health-related quality of life in acute schizophrenia patients treated with rbp-7000 once monthly risperidone: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. |
2018-01-05 |
2023-08-13 |
human |
| John J Isitt, Vijay R Nadipelli, Alex Kouassi, Maurizio Fava, Christian Heidbrede. Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. Schizophrenia research. vol 174. issue 1-3. 2018-01-05. PMID:27066860. |
the aim of this study was to evaluate the impact of treatment with subcutaneous injections of rbp-7000, a new sustained-release formulation of risperidone, compared with placebo on health status, subjective well-being, treatment satisfaction, and preference of medicine in subjects with acute schizophrenia. |
2018-01-05 |
2023-08-13 |
human |
| Hiroshi Kimura, Nobuhisa Kanahara, Tsuyoshi Sasaki, Naoya Komatsu, Minoru Ishige, Katsumasa Muneoka, Hidetoshi Ino, Kazuyuki Yoshimura, Hiroshi Yamanaka, Tomotaka Suzuki, Hideki Komatsu, Hiroyuki Watanabe, Eiji Shimizu, Masaomi Iy. Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up. Journal of psychopharmacology (Oxford, England). vol 30. issue 8. 2018-01-04. PMID:27371496. |
risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: results of a 2-year prospective study, including an additional 1-year follow-up. |
2018-01-04 |
2023-08-13 |
Not clear |
| Libor Ustohal, Michaela Mayerova, Veronika Hublova, Hana Prikrylova Kucerova, Eva Ceskova, Tomas Kaspare. Risperidone increases the cortical silent period in drug-naive patients with first-episode schizophrenia: A transcranial magnetic stimulation study. Journal of psychopharmacology (Oxford, England). vol 31. issue 4. 2018-01-04. PMID:27527735. |
risperidone increases the cortical silent period in drug-naive patients with first-episode schizophrenia: a transcranial magnetic stimulation study. |
2018-01-04 |
2023-08-13 |
Not clear |
| Robabeh Mazinani, Somayeh Nejati, Mohammadreza Khodae. Effects of memantine added to risperidone on the symptoms of schizophrenia: A randomized double-blind, placebo-controlled clinical trial. Psychiatry research. vol 247. 2017-12-11. PMID:27940324. |
effects of memantine added to risperidone on the symptoms of schizophrenia: a randomized double-blind, placebo-controlled clinical trial. |
2017-12-11 |
2023-08-13 |
Not clear |
| Robabeh Mazinani, Somayeh Nejati, Mohammadreza Khodae. Effects of memantine added to risperidone on the symptoms of schizophrenia: A randomized double-blind, placebo-controlled clinical trial. Psychiatry research. vol 247. 2017-12-11. PMID:27940324. |
this study aimed to evaluate the effects of 20mg of memantine per day (as a nmda receptor antagonist) added to risperidone among male patients with schizophrenia. |
2017-12-11 |
2023-08-13 |
Not clear |
| Lingzhi Wu, Xiaowen Feng, Tingting Li, Baojuan Sun, Muhammad Zahid Khan, Ling H. Risperidone ameliorated Aβ Behavioural brain research. vol 322. issue Pt A. 2017-12-01. PMID:28093254. |
risperidone, an atypical antipsychotic, can improve concentration and cognitive deficit in schizophrenia patients. |
2017-12-01 |
2023-08-13 |
Not clear |
| Błażej Misiak, Dorota Frydecka, Jan A Beszłej, Ahmed A Moustafa, Piotr Tybura, Jolanta Kucharska-Mazur, Agnieszka Samochowiec, Przemysław Bieńkowski, Jerzy Samochowie. Effects of antipsychotics on insight in schizophrenia: results from independent samples of first-episode and acutely relapsed patients. International clinical psychopharmacology. vol 31. issue 4. 2017-11-27. PMID:26836264. |
olanzapine and risperidone were administered to first-episode schizophrenia patients, whereas acutely relapsed schizophrenic patients were treated with olanzapine, perazine and ziprasidone. |
2017-11-27 |
2023-08-13 |
Not clear |
| Larry Alphs, Henry A Nasrallah, Cynthia A Bossie, Dong-Jing Fu, Srihari Gopal, David Hough, Ibrahim Turko. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy. International clinical psychopharmacology. vol 31. issue 4. 2017-11-27. PMID:26974214. |
this was a post-hoc exploratory analysis of a 1-year study of risperidone long-acting injection in patients with stable schizophrenia or schizoaffective disorder (nct00297388; n=323). |
2017-11-27 |
2023-08-13 |
Not clear |
| Jordi Llaudó, Lourdes Anta, Ignacio Ayani, Javier Martínez, Juan Schronen, Margarita Morozova, Mikhail Ivanov, Ibón Gutierr. Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). International clinical psychopharmacology. vol 31. issue 6. 2017-11-27. PMID:27416102. |
phase i, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ism at different dose strengths in patients with schizophrenia or schizoaffective disorder (prisma-1). |
2017-11-27 |
2023-08-13 |
Not clear |
| Jordi Llaudó, Lourdes Anta, Ignacio Ayani, Javier Martínez, Juan Schronen, Margarita Morozova, Mikhail Ivanov, Ibón Gutierr. Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). International clinical psychopharmacology. vol 31. issue 6. 2017-11-27. PMID:27416102. |
the aim of this study was to characterize the pharmacokinetics and to evaluate the safety of risperidone ism in patients with schizophrenia or schizoaffective disorder after a single gluteal intramuscular injection at three different dose strengths (50, 75, and 100 mg). |
2017-11-27 |
2023-08-13 |
Not clear |
| Soode Tajik-Esmaeeli, Ehsan Moazen-Zadeh, Niloofar Abbasi, Seyed V Shariat, Farzin Rezaei, Bahman Salehi, Shahin Akhondzade. Simvastatin adjunct therapy for negative symptoms of schizophrenia: a randomized double-blind placebo-controlled trial. International clinical psychopharmacology. vol 32. issue 2. 2017-11-27. PMID:27941358. |
in this double-blind trial, inpatients with chronic schizophrenia were clinically stabilized on a constant dose of risperidone for at least 4 weeks before the study and were then randomized to receive risperidone (4-6 mg/day) plus either simvastatin (40 mg/day) (n=33) or placebo (n=33) for 8 weeks. |
2017-11-27 |
2023-08-13 |
Not clear |
| Alper Bas, Gozde Gultekin, Said Incir, Tuba Ocek Bas, Murat Emul, Alaatin Dura. Level of serum thioredoxin and correlation with neurocognitive functions in patients with schizophrenia using clozapine and other atypical antipsychotics. Psychiatry research. vol 247. 2017-11-17. PMID:27871032. |
the aim of this study is investigating the relationship between serum thioredoxin levels and cognitive functions in acute psychotic episode and remission state patients with schizophrenia; and examining whether there were differences between patients using clozapine and other atypical antipsychotics; including risperidone, olanzapine and amisulpride. |
2017-11-17 |
2023-08-13 |
Not clear |